Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment   source : Www.anavex.com    save search
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published: 2021-06-28 (Crawled : 12:00) - anavex.com
AVXL | News | $3.8 0.0% 2.1M twitter stocktwits trandingview |
Health Technology
 | | O: 20.0% H: 6.06% C: -2.83%
disease treatment phase 2 dementia correlation parkinson life science trial anavex®2-73 anavex biomarkers
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions
Published: 2021-06-03 (Crawled : 11:00) - anavex.com
AVXL | News | $3.8 0.0% 2.1M twitter stocktwits trandingview |
Health Technology
 | | O: -0.61% H: 5.41% C: 4.72%
treatment life science patent anavex®2-73 anavex application
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.